Key points from article :
Trojan horse drug shows promising results across six different forms of the disease.
Tisotumab vedotin (TV) destroys tumours from the inside.
Combines chemotherapy agent with an antibody which binds to markers on the surface of cancer cells.
Effects lasted an average of 5.7 months in patients no longer responding to standard drugs.
Worked in bladder, ovarian, lung, oesophageal and cervical cancers, but not prostate cancer.
Targeting allows higher doses of cancer drug with manageable side effects.
Now moving on to larger, stage two clinical trial in cervical cancer.
The study was published in the journal Lancet Oncology.
